A Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Inebilizumab in Children With Generalized Myasthenia Gravis (gMG)
Generalized Myasthenia Gravis
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
- +1.9
3 insiders sold shares within a month
Since Aug 13, 2026 · was worth 5, fading over time
Score over time
- Stage
- Phase 2
- Patients
- 15 (planned)
- Started
- Jul 21, 2026
- Main results expected
- Mar 13, 2030
- Fully finished
- Mar 13, 2030
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Maximum Observed Concentration (Cmax) of Inebilizumab
Measured over: Up to Week 52
Area Under the Concentration-time Curve (AUC) of Inebilizumab
Measured over: Up to Week 52
Half-life (t1/2) of Inebilizumab
Measured over: Up to Week 52
Clearance (CL) of Inebilizumab
Measured over: Up to Week 52
Volume of Distribution at Steady State (Vss) of Inebilizumab
Measured over: Up to Week 52
Change from Baseline in Cluster of Differentiation 20 (CD20)+ B-cell Counts
Measured over: Baseline and Week 78
Number of Participants Experiencing Treatment-emergent Adverse Events
Measured over: Up to Week 78
Number of Participants Experiencing Clinically Significant Changes in Laboratory Parameters
Measured over: Up to Week 78
Number of Participants Experiencing Clinically Significant Changes in Vital Signs
Measured over: Up to Week 78
Changes Tremor has spotted
Show details (technical version)
Score inputs
- insider_selling_cluster: base 5, now 1.9, since 2026-08-13, fades (half-life)
Raw record changes
- none yet
Trial ID NCT06987539 · record last updated 2026-10-23 · checked 2026-11-09 15:47 UTC